Doximity, Inc. (NASDAQ:DOCS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Doximity, Inc. (NASDAQ:DOCS) has been assigned an average recommendation of “Moderate Buy” from the twenty-one ratings firms that are currently covering the firm, Marketbeat reports. Eleven analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $64.22.

A number of research firms have recently commented on DOCS. Raymond James reiterated an “outperform” rating and issued a $83.00 price objective (up from $65.00) on shares of Doximity in a research note on Friday, February 7th. The Goldman Sachs Group lifted their price target on Doximity from $58.00 to $80.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. Needham & Company LLC upped their target price on shares of Doximity from $65.00 to $82.00 and gave the company a “buy” rating in a research note on Friday, February 7th. KeyCorp reduced their target price on shares of Doximity from $70.00 to $65.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Finally, Stephens assumed coverage on Doximity in a report on Friday, December 20th. They issued an “equal weight” rating and a $55.00 price target for the company.

Insiders Place Their Bets

In other Doximity news, Director Timothy S. Cabral sold 20,000 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $57.62, for a total transaction of $1,152,400.00. Following the transaction, the director now owns 6,360 shares of the company’s stock, valued at approximately $366,463.20. This represents a 75.87 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 37.40% of the company’s stock.

Institutional Investors Weigh In On Doximity

A number of institutional investors and hedge funds have recently made changes to their positions in the company. QSV Equity Investors LLC increased its stake in Doximity by 0.3% in the fourth quarter. QSV Equity Investors LLC now owns 60,763 shares of the company’s stock valued at $3,244,000 after purchasing an additional 186 shares in the last quarter. Handelsbanken Fonder AB grew its holdings in shares of Doximity by 0.7% in the 4th quarter. Handelsbanken Fonder AB now owns 29,700 shares of the company’s stock valued at $1,586,000 after buying an additional 200 shares during the period. UMB Bank n.a. increased its position in shares of Doximity by 69.1% in the 4th quarter. UMB Bank n.a. now owns 575 shares of the company’s stock valued at $31,000 after buying an additional 235 shares in the last quarter. Fielder Capital Group LLC raised its stake in Doximity by 4.5% during the 4th quarter. Fielder Capital Group LLC now owns 5,488 shares of the company’s stock worth $293,000 after buying an additional 235 shares during the period. Finally, Larson Financial Group LLC lifted its holdings in Doximity by 49.4% during the fourth quarter. Larson Financial Group LLC now owns 756 shares of the company’s stock worth $40,000 after acquiring an additional 250 shares in the last quarter. Institutional investors own 87.19% of the company’s stock.

Doximity Price Performance

Shares of DOCS opened at $77.13 on Friday. The company has a market capitalization of $14.40 billion, a PE ratio of 77.13, a price-to-earnings-growth ratio of 4.61 and a beta of 1.39. Doximity has a one year low of $22.96 and a one year high of $85.21. The company’s fifty day moving average price is $57.89 and its 200 day moving average price is $47.37.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.